Freestyle Libre-based Education on MDI in T2DM (FreEdoM-2)
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
FreeStyle Libre
SMBG
Sponsored by

About this trial
This is an interventional health services research trial for Type 2 Diabetes Mellitus
Eligibility Criteria
Inclusion Criteria:
- Type 2 diabetes patients aged 19 and under 75 years.
- Multiple insulin injections at the time of screening (at least one base insulin and two fast-acting insulin) or those who have been using an insulin pump for at least 12 weeks
- HbA1c of not less than 7.5% and not more than 12.0% at the time of screening
Sites / Locations
- Samsung Medical Center
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Active Comparator
Active Comparator
Arm Label
CGM with Structured Education
CGM with Standard Education
SMBG with Standard Education
Arm Description
CGM with Structured Education
CGM with Standard Education
SMBG with Standard Education
Outcomes
Primary Outcome Measures
HbA1c (%) changes at 24 weeks compared to baseline
Secondary Outcome Measures
Full Information
NCT ID
NCT04926623
First Posted
June 10, 2021
Last Updated
June 22, 2023
Sponsor
Daewoong Pharmaceutical Co. LTD.
1. Study Identification
Unique Protocol Identification Number
NCT04926623
Brief Title
Freestyle Libre-based Education on MDI in T2DM (FreEdoM-2)
Official Title
Multicenter, Open-label, Randomized Trial to Compare the Effectiveness of Structured Education and Safety of FreeStyle Libre or Self-Monitoring of Blood Glucose (SMBG) in Patients With Type 2 Diabetes Mellitus Using Multiple Daily Injections or Insulin Pumps
Study Type
Interventional
2. Study Status
Record Verification Date
June 2021
Overall Recruitment Status
Completed
Study Start Date
June 17, 2021 (Actual)
Primary Completion Date
October 26, 2022 (Actual)
Study Completion Date
April 4, 2023 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Daewoong Pharmaceutical Co. LTD.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Multicenter, Open-label, Randomized Trial to Compare the Effectiveness of Structured Education and Safety of FreeStyle Libre or Self-Monitoring of Blood Glucose (SMBG) in patients with type 2 Diabetes Mellitus using Multiple Daily Injections or Insulin Pumps
Detailed Description
All subjects must participate in Blind Continuous Glucose Monitoring(CGM) for two weeks prior to Visit 2 visit (random assignment).
Subjects who meet the selection/exclusion criteria in Visit 2 visits are randomly assigned to the test group (personal in-depth education and FreeStyle Libre) or control 1 (standard education and FreeStyle Libre) or control 2 (standard education and SMBG) at a 1:1:1 ratio.
In the test group, personal in-depth education is conducted at baseline (Visit 2), 4 weeks (Visit 3), 8 weeks (Visit 4), 12 weeks (Visit 5), and 18 weeks (Visit 6), and the time required for education and preparation time required for patient education are checked.
Control groups 1 and 2 conduct routine insulin basic injection training as standard education at baseline (Visit 2) and 12 weeks (Visit 5).
After randomization, FreeStyle Libre is applied to the test group and control group 1 for 24 weeks, and SMBG is performed for 22 weeks and Blind CGM is applied for 2 weeks at 22 weeks (Visit 7).
Blood glucose measurements collected from FreeStyle Libre are collected through the reader program, and are checked in real time by researchers and used for education, research, and analysis. Prior to the implementation of FreeStyle Libre for the collection of real-time blood sugar collected through FreeStyle Libre, the subject is given consent to disclose blood sugar information.
All subjects visit baseline (Visit 2), 12 weeks (Visit 5), and 24 weeks (Visit 8) to conduct surveys on physical examinations, blood tests and urine tests (Central Lab), and treatment satisfaction questionnaire (DTSQ).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
7. Study Design
Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
159 (Actual)
8. Arms, Groups, and Interventions
Arm Title
CGM with Structured Education
Arm Type
Experimental
Arm Description
CGM with Structured Education
Arm Title
CGM with Standard Education
Arm Type
Active Comparator
Arm Description
CGM with Standard Education
Arm Title
SMBG with Standard Education
Arm Type
Active Comparator
Arm Description
SMBG with Standard Education
Intervention Type
Device
Intervention Name(s)
FreeStyle Libre
Intervention Description
FreeStyle Libre flash sensor-based glucose monitoring system (FSGM; Abbott Diabetes Care, Witney, Oxon, UK)
Intervention Type
Other
Intervention Name(s)
SMBG
Intervention Description
Self-Monitoring of Blood Glucose
Primary Outcome Measure Information:
Title
HbA1c (%) changes at 24 weeks compared to baseline
Time Frame
6 months after randomization
10. Eligibility
Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Type 2 diabetes patients aged 19 and under 75 years.
Multiple insulin injections at the time of screening (at least one base insulin and two fast-acting insulin) or those who have been using an insulin pump for at least 12 weeks
HbA1c of not less than 7.5% and not more than 12.0% at the time of screening
Facility Information:
Facility Name
Samsung Medical Center
City
Seoul
ZIP/Postal Code
135-710
Country
Korea, Republic of
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Freestyle Libre-based Education on MDI in T2DM (FreEdoM-2)
We'll reach out to this number within 24 hrs